Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People (women and men) who were diagnosed with early to locally advanced breast cancer (stage I–III) that is either triple-negative (TNBC) or HER2-positive, including those with tumours that have low levels of hormone receptors (1–10%)
- People whose cancer is of any tissue type under the microscope
- People who had no cancer detected in the lymph nodes under the arm at diagnosis, where any standard method of checking the lymph nodes is acceptable
- People who had lymph node involvement confirmed by a needle biopsy at diagnosis, and who then had one of several specific types of lymph node surgery after chemotherapy (confirm with trial site for which procedures qualify)
- People who received chemotherapy before surgery (called neoadjuvant chemotherapy)
- People who had cancer deposits larger than 2 mm found in their lymph nodes during surgery after chemotherapy
- People whose other sentinel lymph nodes contained only very small amounts of cancer (tiny cell clusters or very small deposits) alongside the larger deposit
- People who, after their lymph node surgery, went on to have full lymph node removal, radiation to the lymph nodes, both, or neither
- People who had their surgery at any point up to October 2024 and have at least one year of follow-up since then
- People with a prior history of a non-invasive breast condition called ductal carcinoma in situ (DCIS)
Who may not be able to join:
- People who went directly to full lymph node removal under the arm without first having the more limited lymph node surgery procedures described above
- People whose lymph node findings after chemotherapy showed only very small amounts of cancer (tiny cell clusters or very small deposits) but no larger cancer deposits
- People whose breast cancer is hormone receptor-positive and HER2-negative (unless the hormone receptor levels are in the low range of 1–10%)
- People who had stage IV (metastatic) breast cancer at the time of their original diagnosis
- People who had inflammatory breast cancer at the time of their original diagnosis
- People who received hormone-blocking therapy before surgery instead of, or rather than, chemotherapy
- People where larger cancer deposits in the lymph nodes were detected using a specific molecular testing method called OSNA, rather than standard pathology examination
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Walter P. Weber, Prof. Dr. med., Department Breast, Abdomen, Pelvis
Phone: +41 61 328 61 49
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
3-year rate of any axillary recurrence
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.